LNP1265

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals

Conditions

Hemophilia B

Phase 1

A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/CAS9-Based Coagulation Factor IX Gene Insertion Therapy in Participants with Hemophilia B

RecruitingCTIS2023-507260-40-00

Regeneron Pharmaceuticals Inc.Hemophilia B

Start: 2025-06-16Target: 22Updated: 2025-05-26

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

RecruitingNCT06379789

Regeneron PharmaceuticalsHemophilia B

Start: 2024-09-11End: 2047-08-14Target: 130Updated: 2026-09-11